Universitätsklinik
für Innere Medizin II Innsbruck

(Infektiologie, Immunologie, Tropenmedizin, Rheumatologie, Pneumologie)
Medizinische Universität Innsbruck

Home > Forschung > CovILD Studie

Development of Interstitial Lung Disease (ILD) in Patients With Severe SARS-CoV-2 Infection (COVID-19) (CovILD)
 

https://clinicaltrials.gov/ct2/show/NCT04416100  
 

COVID-19, the infectious disease caused by the novel coronavirus SARS-CoV-2, currently poses a global economic, social, political and medical challenge.
The most common computed tomographic changes in acute lung injury include bilateral and subpleural ground glass opacity, consolidation in lower lobes, or both. In the intermediate phase of the infection (4-14 days after the onset of symptoms) a so-called "crazy paving" may occur.
Given the phylogenetic relationship between SARS-CoV-1 and SARS-CoV-2, the similar clinical course in severe cases and overlapping CT patterns in the acute setting, persistent radiological and pulmonary functional changes in survivors are conceivable. It is also conceivable that a proportion of survivors will develop progressive ILD, either due to viral or ventilator-induced alveolar damage, or both.
In this prospective, multicenter study the investigators intend to investigate COVID-19 survivors through clinical examinations, functional lung examinations, cardiological assessments, and HR-CT scans 1.5, 3, and 6 months after discharge.

The Development of Interstitial Lung Disease in Patients With Severe SARS-CoV-2 Infection (CovILD) study group is composed of specialists in infectious diseases and pneumology, radiology, cardiology, neurology, bioinformatics, and epidemiology:

Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria (T. Sonnweber MD, S. Sahanic MD, A. Pizzini MD, K. Kurz MD, D. Haschka MD, A. Boehm MD, R. Hilbe, S. Koppelstätter MD, C. Tschurtschenthaler MD, M. Asshoff MD, M. Nairz MD, A. Schroll MD, A. Tancevski MD, G. Fritsche MD, S. Wildner MD, R. Bellmann-Weiler MD, G. Weiss MD, J. Löffler-Ragg MD., I. Tancevski MD); Department of Radiology, Medical University of Innsbruck, Innsbruck, Austria (C. Schwabl MD, A. Luger MD, G. Feuchtner MD, G. Widmann MD); Department of Internal Medicine V, Medical University of Innsbruck, Innsbruck, Austria (V. Petzer MD); Department of Internal Medicine I, Medical University of Innsbruck, Innsbruck, Austria (R. Bellmann MD, M. Joannidis MD, A. Peer MD, F. Hartig MD); Department of Internal Medicine III, Medical University of Innsbruck, Innsbruck, Austria (D. Lener, M. Theurl MD, R. Kirchmair MD); Department of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria (C. Gollmann-Tepekölyü MD, J. Holfeld MD); Department of Central Laboratory Facility, Medical University of Innsbruck, Innsbruck, Austria (A. Egger MD, G. Hörmann MD); Department of Internal Medicine, St. Vinzenz Hospital, Zams, Austria (M. Schaber MD, A. Schapfl MD, B Sonnweber MD, E. Wöll MD); The Karl Landsteiner Institute, Reha Zentrum Münster, Münster, Austria (B. Puchner MD, R. Kirchmair MD); Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria (R. Helbok MD, A. Heidbreder MD, B. Högl MD); Institute for Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria (D. Rieder, Z. Trajanoski PhD); Institute of Genetic Epidemiology, Medical University of Innsbruck, Innsbruck, Austria (F. Kronenberg MD); Department of Biomedical Imaging and Image-guided Therapy, Medical University Vienna, Vienna, Austria (H. Prosch MD).

 

 

Universitätsklinik für Innere Medizin II Innsbruck | Anichstrasse 35, A-6020 Innsbruck | Tel.: +43(0)512504-23251, Fax: +43(0)512504-23317